New G Lab Pharma

New G Lab Pharma is a South Korean biotechnology company specializing in the development of metabolic anticancer therapies. Its flagship program, KAT (3-bromopyruvate), is a small molecule inhibitor designed to disrupt the energy metabolism of cancer cells by targeting hexokinase 2 and other glycolytic enzymes. The company is also advancing targeted therapies, such as the ROS1/NTRK inhibitor taletrectinib, which it licensed for development and commercialization in the Korean market. New G Lab Pharma aims to address high unmet medical needs in oncology, particularly for difficult-to-treat conditions like hepatocellular carcinoma and non-small cell lung cancer. In addition to its R&D pipeline, the company maintains business interests in pharmaceutical distribution and medical devices.